Literature DB >> 24918530

Costs of Diabetes Mellitus (CoDiM) in Germany, direct per-capita costs of managing hyperglycaemia and diabetes complications in 2010 compared to 2001.

I Köster1, E Huppertz2, H Hauner3, I Schubert1.   

Abstract

INTRODUCTION: To identify direct health care costs of patients with diabetes in Germany in 2010, with focus on costs of treating hyperglycaemia and costs caused by diabetes complications, and to compare findings with results from the CoDiM study 2001.
MATERIAL AND METHODS: The cost analysis was based on administrative data (18.75% random sample of 1.5 million insured persons). Medical costs covered by statutory health insurance and costs covered by nursing care insurance were included. Incremental differences in costs of patients with diabetes (n=30 987) and age and sex-matched subjects without a diagnosis of diabetes (controls) were estimated according to the number and type of complications. Costs were standardised to the German population.
RESULTS: In 2010, incremental medical costs attributed to diabetes were € 2 391 (95% confidence interval: 2 257-2 524) per patient with diabetes. Of that amount, 26.5% were spent for the management of hyperglycaemia (€ 633 (622-644)) and 73.5% for the treatment of comp-lications (€ 1 758 (1 627-1 889)). Nursing care contributed incremental costs of € 289 (249-330), of which 98.8% was due to complications. From 2001 to 2010 the incremental per-capita costs for medical and nursing care decreased by 4.8% (controls: +3.9%), the per-capita costs for treating hyperglycaemia increased by 2.0% and the per-capita costs for complications decreased by 7.0%.
CONCLUSION: Cost for diabetes is largely caused by management of complications. It is important to prevent complications by consequent management of diabetes as well as by primary prevention of its onset. © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2014        PMID: 24918530     DOI: 10.1055/s-0034-1375675

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  12 in total

1.  Impact of Disease Management Programs on HbA1c Values in Type 2 Diabetes Patients in Germany.

Authors:  Karel Kostev; Timo Rockel; Louis Jacob
Journal:  J Diabetes Sci Technol       Date:  2016-07-10

2.  Prescription Patterns and the Cost of Antihyperglycemic Drugs in Patients With Type 2 Diabetes Mellitus in Germany.

Authors:  Louis Jacob; Christian von Vultee; Karel Kostev
Journal:  J Diabetes Sci Technol       Date:  2016-07-11

3.  Self-reported Hypoglycaemic Events in 2 430 Patients with Insulin-treated Diabetes in the German Sub-population of the HAT Study.

Authors:  Werner Kern; Andreas Holstein; Christian Moenninghoff; Joachim Kienhöfer; Matthias Riedl; Bernhard Kulzer
Journal:  Exp Clin Endocrinol Diabetes       Date:  2017-07-27       Impact factor: 2.949

4.  [Imaging in syndrome complex diabetes mellitus: Current standards and future perspectives].

Authors:  H Hetterich; A Schafnitzel; F Bamberg
Journal:  Radiologe       Date:  2015-04       Impact factor: 0.635

5.  Early discontinuation and related treatment costs after initiation of Basal insulin in type 2 diabetes patients: a German primary care database analysis.

Authors:  Helmut Anderten; Franz-Werner Dippel; Karel Kostev
Journal:  J Diabetes Sci Technol       Date:  2015-01-07

Review 6.  Is fenofibrate a reasonable treatment for diabetic microvascular disease?

Authors:  Rafael Simó; Olga Simó-Servat; Cristina Hernández
Journal:  Curr Diab Rep       Date:  2015-05       Impact factor: 4.810

7.  Cost burden of type 2 diabetes in Germany: results from the population-based KORA studies.

Authors:  Susanne Ulrich; Rolf Holle; Margarethe Wacker; Renee Stark; Andrea Icks; Barbara Thorand; Annette Peters; Michael Laxy
Journal:  BMJ Open       Date:  2016-11-21       Impact factor: 2.692

8.  Quality of Diabetes Care in Germany Improved from 2000 to 2007 to 2014, but Improvements Diminished since 2007. Evidence from the Population-Based KORA Studies.

Authors:  Michael Laxy; Gabriella Knoll; Michaela Schunk; Christa Meisinger; Cornelia Huth; Rolf Holle
Journal:  PLoS One       Date:  2016-10-17       Impact factor: 3.240

Review 9.  The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development.

Authors:  Fan Hong; Pengfei Xu; Yonggong Zhai
Journal:  Int J Mol Sci       Date:  2018-07-27       Impact factor: 5.923

10.  Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain.

Authors:  Manel Mata-Cases; Marc Casajuana; Josep Franch-Nadal; Aina Casellas; Conxa Castell; Irene Vinagre; Dídac Mauricio; Bonaventura Bolíbar
Journal:  Eur J Health Econ       Date:  2015-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.